A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Jennifer R. Diamond(University of Colorado Cancer Center), Kathy D. Miller(Indiana University Health)

Breast Cancer Research

August 2, 2018

10.1186/s13058-018-1014-y

Cited by 69

Related Papers

Initial Phase I Safety Study of Gedatolisib plus Cofetuzumab Pelidotin for Patients with Metastatic Triple-Negative Breast Cancer

|Clinical Cancer Research|2022|29

Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer

|Frontiers in Oncology|2017|22

First-in-Human Dose-Escalation Study of the Novel Oral Depsipeptide Class I-Targeting HDAC Inhibitor Bocodepsin (OKI-179) in Patients with Advanced Solid Tumors

|Cancers|2023|10

Change, Change, We've Got Change!

|Computers in libraries: Complete coverage of library information technology|1999|0